CN108367093A - 用于止血、组织屏障、创伤愈合和美容的生物相容性羧甲基纤维素基质(bcm) - Google Patents
用于止血、组织屏障、创伤愈合和美容的生物相容性羧甲基纤维素基质(bcm) Download PDFInfo
- Publication number
- CN108367093A CN108367093A CN201680071172.5A CN201680071172A CN108367093A CN 108367093 A CN108367093 A CN 108367093A CN 201680071172 A CN201680071172 A CN 201680071172A CN 108367093 A CN108367093 A CN 108367093A
- Authority
- CN
- China
- Prior art keywords
- biocompatibility
- carboxymethyl cellulose
- wound
- bcm
- treatment device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002134 Carboxymethyl cellulose Polymers 0.000 title claims abstract description 70
- 235000010948 carboxy methyl cellulose Nutrition 0.000 title claims abstract description 68
- 239000001768 carboxy methyl cellulose Substances 0.000 title claims abstract description 67
- 239000008112 carboxymethyl-cellulose Substances 0.000 title claims abstract description 67
- 230000004888 barrier function Effects 0.000 title claims abstract description 22
- 230000003796 beauty Effects 0.000 title claims abstract description 10
- 230000029663 wound healing Effects 0.000 title claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 58
- 238000011282 treatment Methods 0.000 claims abstract description 52
- 230000023597 hemostasis Effects 0.000 claims abstract description 30
- 208000032843 Hemorrhage Diseases 0.000 claims description 34
- 239000004744 fabric Substances 0.000 claims description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 30
- 230000000740 bleeding effect Effects 0.000 claims description 29
- 238000006116 polymerization reaction Methods 0.000 claims description 27
- 238000006467 substitution reaction Methods 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 230000006378 damage Effects 0.000 claims description 18
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
- 239000002759 woven fabric Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 14
- 230000001737 promoting effect Effects 0.000 claims description 13
- 229920000297 Rayon Polymers 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 9
- 239000000835 fiber Substances 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 238000009987 spinning Methods 0.000 claims description 8
- 229920000742 Cotton Polymers 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 230000002439 hemostatic effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000000746 purification Methods 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- -1 mesh Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 210000001367 artery Anatomy 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 239000000084 colloidal system Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 159000000000 sodium salts Chemical group 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 159000000013 aluminium salts Chemical class 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 238000009954 braiding Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 description 78
- 206010052428 Wound Diseases 0.000 description 76
- 210000003491 skin Anatomy 0.000 description 49
- 208000034158 bleeding Diseases 0.000 description 29
- 231100000319 bleeding Toxicity 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 22
- 239000010410 layer Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 239000000499 gel Substances 0.000 description 12
- 238000001804 debridement Methods 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 210000004761 scalp Anatomy 0.000 description 9
- 230000000025 haemostatic effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000004936 stimulating effect Effects 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 206010003162 Arterial injury Diseases 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 231100000075 skin burn Toxicity 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000028990 Skin injury Diseases 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000036560 skin regeneration Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- 206010040840 Skin erosion Diseases 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000036376 Femoral artery occlusion Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AMFGWXWBFGVCKG-UHFFFAOYSA-N Panavia opaque Chemical compound C1=CC(OCC(O)COC(=O)C(=C)C)=CC=C1C(C)(C)C1=CC=C(OCC(O)COC(=O)C(C)=C)C=C1 AMFGWXWBFGVCKG-UHFFFAOYSA-N 0.000 description 2
- 208000037486 Postoperative Hemorrhage Diseases 0.000 description 2
- 235000013290 Sagittaria latifolia Nutrition 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000004036 ankyloblepharon-ectodermal defects-cleft lip/palate syndrome Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000015246 common arrowhead Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- SJRXVLUZMMDCNG-UHFFFAOYSA-N Gossypin Natural products OC1C(O)C(O)C(CO)OC1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=C(O)C2=O SJRXVLUZMMDCNG-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010054786 Skin burning sensation Diseases 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- SJRXVLUZMMDCNG-KKPQBLLMSA-N gossypin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C=C(O)C2=C1OC(C=1C=C(O)C(O)=CC=1)=C(O)C2=O SJRXVLUZMMDCNG-KKPQBLLMSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000008233 hard water Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 230000037377 skin turgor Effects 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000019795 sodium metasilicate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940035658 visco-gel Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/08—Cellulose derivatives
- C08L1/26—Cellulose ethers
- C08L1/28—Alkyl ethers
- C08L1/286—Alkyl ethers substituted with acid radicals, e.g. carboxymethyl cellulose [CMC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238676P | 2015-10-07 | 2015-10-07 | |
| US62/238,676 | 2015-10-07 | ||
| PCT/US2016/036100 WO2017062072A1 (en) | 2015-10-07 | 2016-06-06 | Biocompatible carboxymethylcellulose matrix (bcm) for hemostasis, tissue barrier wound healing, and cosmetology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108367093A true CN108367093A (zh) | 2018-08-03 |
Family
ID=58488241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680071172.5A Pending CN108367093A (zh) | 2015-10-07 | 2016-06-06 | 用于止血、组织屏障、创伤愈合和美容的生物相容性羧甲基纤维素基质(bcm) |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20180280561A1 (https=) |
| EP (1) | EP3359206A4 (https=) |
| JP (1) | JP6807922B2 (https=) |
| CN (1) | CN108367093A (https=) |
| WO (1) | WO2017062072A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111840633A (zh) * | 2019-04-29 | 2020-10-30 | 上海硅健生物材料有限公司 | 一种皮肤修复膜及其制备方法 |
| CN115046907A (zh) * | 2022-08-15 | 2022-09-13 | 启东市鸿盛纺织有限公司 | 一种可吸收止血纱布的质量评估方法及系统 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107604739B (zh) * | 2017-09-26 | 2019-06-07 | 江南大学 | 一种过滤用棉秆皮纤维与壳聚糖复合非织布的制备方法 |
| EP4164704A4 (en) * | 2020-06-10 | 2024-07-10 | The Australian National University | Haemostatic material |
| WO2024049708A1 (en) * | 2022-08-30 | 2024-03-07 | Lifescienceplus, Inc. | Wound healing and related products and methods thereof for regulating tissue growth factors for healing |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3965091A (en) * | 1973-11-22 | 1976-06-22 | Hoechst Aktiengesellschaft | Process for the production of water-adsorbing but water-insoluble cellulose ethers |
| SU1405145A3 (ru) * | 1983-06-20 | 1999-10-20 | Московская медицинская академия им.И.М.Сеченова | Способ получения средства для лечения гнойных ран |
| EP0956869A2 (en) * | 1998-05-15 | 1999-11-17 | Hogy Medical Co., Ltd. | Tissue sealant |
| JPH11322614A (ja) * | 1998-05-15 | 1999-11-24 | Hogi Medical:Kk | 細胞接着促進効果を有する創傷止血材 |
| JP2002369874A (ja) * | 2001-06-14 | 2002-12-24 | Terumo Corp | 止血材料 |
| CN1505530A (zh) * | 2001-04-30 | 2004-06-16 | ������֯��ѧ�о��� | 水溶性纤维素醚化衍生物止血材料 |
| RU2249467C2 (ru) * | 2002-11-25 | 2005-04-10 | ООО Научно-производственное предприятие "ЭРЛОН", Лтд. | Медицинский материал и изделия на его основе |
| RU2353626C1 (ru) * | 2007-10-25 | 2009-04-27 | Институт химии растворов РАН | Способ получения волокнистой целлюлозы из целлюлозосодержащего волокна |
| CN102908650A (zh) * | 2012-09-25 | 2013-02-06 | 北京维索科科技有限公司 | 可溶性止血材料生产工艺 |
| CN103041437A (zh) * | 2012-12-25 | 2013-04-17 | 武汉纺织大学 | 一种高强度、高吸水性含羧甲基纤维素医用敷料及其制备方法 |
| CN103120802A (zh) * | 2012-07-26 | 2013-05-29 | 佛山市优特医疗科技有限公司 | 可溶性止血纱布及其制备方法 |
| CN104389155A (zh) * | 2014-12-18 | 2015-03-04 | 山东蓝汀制药有限公司 | 一种医用材料及制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1405145A (en) * | 1919-11-10 | 1922-01-31 | Morse Chain Co | Method of correcting the pitch in drive chains |
| CN102014973A (zh) * | 2008-02-29 | 2011-04-13 | 弗罗桑医疗设备公司 | 用于促进止血和/或伤口愈合的装置 |
| CN109260500A (zh) * | 2013-05-09 | 2019-01-25 | 旭化成株式会社 | 使用了羧甲基纤维素的医疗用材料 |
-
2016
- 2016-06-06 JP JP2018517351A patent/JP6807922B2/ja active Active
- 2016-06-06 EP EP16854020.1A patent/EP3359206A4/en not_active Withdrawn
- 2016-06-06 CN CN201680071172.5A patent/CN108367093A/zh active Pending
- 2016-06-06 US US15/766,174 patent/US20180280561A1/en not_active Abandoned
- 2016-06-06 WO PCT/US2016/036100 patent/WO2017062072A1/en not_active Ceased
-
2021
- 2021-10-03 US US17/492,618 patent/US20220072192A1/en not_active Abandoned
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3965091A (en) * | 1973-11-22 | 1976-06-22 | Hoechst Aktiengesellschaft | Process for the production of water-adsorbing but water-insoluble cellulose ethers |
| SU1405145A3 (ru) * | 1983-06-20 | 1999-10-20 | Московская медицинская академия им.И.М.Сеченова | Способ получения средства для лечения гнойных ран |
| EP0956869A2 (en) * | 1998-05-15 | 1999-11-17 | Hogy Medical Co., Ltd. | Tissue sealant |
| JPH11322614A (ja) * | 1998-05-15 | 1999-11-24 | Hogi Medical:Kk | 細胞接着促進効果を有する創傷止血材 |
| US20060014721A1 (en) * | 2001-04-30 | 2006-01-19 | Beijing Textile Research Institute | Water soluble cellulose etherified derivatives styptic materials |
| CN1505530A (zh) * | 2001-04-30 | 2004-06-16 | ������֯��ѧ�о��� | 水溶性纤维素醚化衍生物止血材料 |
| JP2002369874A (ja) * | 2001-06-14 | 2002-12-24 | Terumo Corp | 止血材料 |
| RU2249467C2 (ru) * | 2002-11-25 | 2005-04-10 | ООО Научно-производственное предприятие "ЭРЛОН", Лтд. | Медицинский материал и изделия на его основе |
| RU2353626C1 (ru) * | 2007-10-25 | 2009-04-27 | Институт химии растворов РАН | Способ получения волокнистой целлюлозы из целлюлозосодержащего волокна |
| CN103120802A (zh) * | 2012-07-26 | 2013-05-29 | 佛山市优特医疗科技有限公司 | 可溶性止血纱布及其制备方法 |
| CN102908650A (zh) * | 2012-09-25 | 2013-02-06 | 北京维索科科技有限公司 | 可溶性止血材料生产工艺 |
| CN103041437A (zh) * | 2012-12-25 | 2013-04-17 | 武汉纺织大学 | 一种高强度、高吸水性含羧甲基纤维素医用敷料及其制备方法 |
| CN104389155A (zh) * | 2014-12-18 | 2015-03-04 | 山东蓝汀制药有限公司 | 一种医用材料及制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 张萍主编: "《纺织材料学》", 30 September 2008, 北京：中国轻工业出版社 * |
| 王静等: "《慢性伤口护理及案例分享》", 31 October 2014, 上海：第二军医大学出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111840633A (zh) * | 2019-04-29 | 2020-10-30 | 上海硅健生物材料有限公司 | 一种皮肤修复膜及其制备方法 |
| CN111840633B (zh) * | 2019-04-29 | 2022-08-23 | 上海硅健生物材料有限公司 | 一种皮肤修复膜及其制备方法 |
| CN115046907A (zh) * | 2022-08-15 | 2022-09-13 | 启东市鸿盛纺织有限公司 | 一种可吸收止血纱布的质量评估方法及系统 |
| CN115046907B (zh) * | 2022-08-15 | 2022-10-28 | 启东市鸿盛纺织有限公司 | 一种可吸收止血纱布的质量评估方法及系统 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3359206A1 (en) | 2018-08-15 |
| WO2017062072A1 (en) | 2017-04-13 |
| US20180280561A1 (en) | 2018-10-04 |
| JP6807922B2 (ja) | 2021-01-06 |
| US20220072192A1 (en) | 2022-03-10 |
| JP2018536630A (ja) | 2018-12-13 |
| EP3359206A4 (en) | 2019-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220072192A1 (en) | Biocompatible carboxymethylcellulose matrix (bcm) for hemostasis, tissue barrier, wound healing, and cosmetology | |
| AU2016210617B2 (en) | Hemostatic device | |
| CN108187120A (zh) | 一种麻醉科医用止痛止血敷料及其制备方法 | |
| BR112018009306B1 (pt) | Composição de fibras e/ou agregados hemostáticos à base de celulose, método de fabricação, gel, e método para formação de um gel | |
| CN102908652A (zh) | 一种主要用于急救的复合止血材料 | |
| Meslier et al. | A comprehensive review of clinical studies on bacterial cellulose: from the earliest uses to contemporary innovations | |
| CN107308488A (zh) | 一种含氯化钙和海藻酸钠的止血粉的制备方法 | |
| JP2009514597A (ja) | 生体吸収性止血ガーゼ | |
| CN106975098A (zh) | 一种复合多糖止血组合物及其制备方法与应用 | |
| Grosu-Bularda et al. | Diabetic foot ulcers, a comprehensive approach—Review | |
| CN116570753B (zh) | 一种组织再生型生物膜组织复合物及制备方法及应用 | |
| CN112870430A (zh) | 基于天然多糖的复合凝胶止血粉、其制备方法及应用 | |
| WO2016080158A1 (ja) | 創傷治癒を促進し生体諸臓器の被覆（コーチング）及び庇護を目的とした生体皮膜剤 | |
| CN107715167A (zh) | 作为骨蜡替代物的壳聚糖基止血糊剂及制备方法 | |
| CN117180489A (zh) | 一种微纤维胶原止血材料及其制备方法和应用 | |
| CN109731128A (zh) | 一种可吸收降解的生物相容性止血材料及其制备方法 | |
| TW202024119A (zh) | 雙層蠶絲蛋白敷料及其製造方法 | |
| EP4313187A1 (en) | Wound treatments and methods of stabilizing, protecting, and treating a wound | |
| RU2826069C1 (ru) | Многослойное комбинированное гемостатическое средство местного действия | |
| Tucker et al. | Chitosan‐based agent use for hemostasis after cryptorchidectomy in a horse | |
| CN109529097A (zh) | 一种可溶性止血纱布 | |
| CN114269350A (zh) | 局部止血组合物 | |
| Jing et al. | Repairing Exposed Tendon Wounds with Absorbable Gelatin Sponges and Autologous Split-Thickness Skin Grafts: A Case Series | |
| JP2024079964A (ja) | 皮膚再生を可能にする足場製剤 | |
| Mohiuddin | Journal of Pharmacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180803 |
|
| RJ01 | Rejection of invention patent application after publication |